PAS‑004 fast‑tracked for NF1 plexiform neurofibromas
What happened
The FDA granted fast track designation to PAS‑004, a macrocyclic MEK inhibitor being developed for NF1‑associated plexiform neurofibromas, accelerating its review path for a high‑morbidity rare disease. Fast track status typically means closer interactions with regulators and an expectation for rapid, rolling safety submissions as data accumulate. For rare‑disease programs this amplifies the need for near‑real‑time adverse event collection and clear REMS‑style planning if safety signals emerge. (targetedonc.com)
Why it matters
Pasithea Therapeutics (NASDAQ: KTTA) is the sponsor behind PAS‑004 and issued its announcement on April 1, 2026; the company lists two active early clinical programs for the molecule — an adult study for symptomatic plexiform neurofibromas linked to neurofibromatosis type 1 (ClinicalTrials.gov NCT06961565) and a separate Phase 1 dose‑escalation study in advanced solid tumors (ClinicalTrials.gov NCT06299839). (ir.pasithea.com) (clinicaltrials.gov 1) (clinicaltrials.gov 2) In company-disclosed interim human data, PAS‑004 has shown a tolerability profile dominated by low‑grade treatment‑related events to date and pharmacology consistent with prolonged systemic exposure that could support once‑daily oral dosing. (ascopubs.org) (ir.pasithea.com) PAS‑004 is described by the company as a macrocyclic MEK inhibitor; macrocyclic means the drug is built as a ring‑shaped molecule, which can improve stability and how long it stays in the body, and a MEK inhibitor blocks the enzymes MEK1 and MEK2 that relay growth signals through the mitogen‑activated protein kinase pathway (MAPK), a biochemical signaling chain that can drive tumor growth. Pasithea also describes PAS‑004 as an allosteric inhibitor, meaning it binds a regulatory site on the enzyme (not the enzyme’s active site) to change activity. (ir.pasithea.com) (ascopubs.org) The ongoing Phase 1 dose‑escalation study uses an open‑label modified “3+3” design — open‑label means investigators and patients know the drug being given, and “3+3” is a stepwise cohort scheme where small groups of patients receive escalating doses to find a tolerated range — and as of January 3, 2025 nine patients had been enrolled across 2 mg, 4 mg and 8 mg cohorts with no dose‑limiting toxicities reported; preliminary pharmacokinetic analysis estimated a terminal half‑life of about 70 hours and a steady‑state peak‑to‑trough ratio (Cmax/Cmin) of approximately 1.4. The solid tumor study lists an actual start date of February 29, 2024 and an estimated primary completion date of February 2026 on ClinicalTrials.gov. (ascopubs.org) (clinicaltrials.gov) Regulatory context: FDA expedited‑program guidance and internal procedures document how agencies handle products for serious, unmet‑need conditions and outline the authority to require post‑approval risk‑minimization measures; those same documents also describe sponsor‑agency interactions and program management that can lead to defined postmarketing commitments or risk management requirements later in the lifecycle. (fda.gov 1) (fda.gov 2) (fda.gov 3) Safety‑surveillance implications tied to the mechanism and early data are concrete: published experience with approved and investigational MEK inhibitors documents common class toxicities such as skin reactions and gastrointestinal effects, as well as less frequent but clinically important cardiac effects (reduced left ventricular ejection fraction, i.e., decreased heart pumping function) and ocular events including central serous retinopathy (fluid under the retina that can affect vision). FDA’s finalized best‑practices guidance for postmarketing safety surveillance and the agency’s REMS framework (Risk Evaluation and Mitigation Strategy, a formal safety program the agency can require) are the specific authorities and playbooks regulators cite when they seek protocolized monitoring, ocular/cardiac surveillance schedules, centralized adjudication, and post‑approval study commitments. (ascopubs.org) (accessdata.fda.gov) (academic.oup.com) (federalregister.gov) For teams drafting safety plans, the tangible takeaways in regulatory terms are already documented: expect agency reference to the REMS modification and implementation guidance timelines when proposing any risk‑minimization program, anticipate requests for structured post‑approval safety studies under existing accelerated‑approval statutes if efficacy endpoints are used for earlier approvals, and plan protocol language and data‑capture systems that support near‑real‑time adverse event aggregation and specialized adjudication (for example, ophthalmology and cardiology review paths) should the benefit‑risk calculus require formal mitigation. (fda.gov 1) (fda.gov 2) (federalregister.gov)
Key numbers
- The FDA granted fast track designation to PAS‑004, a macrocyclic MEK inhibitor being developed for NF1‑associated plexiform neurofibromas, accelerating its review path for a high‑morbidity rare disease.
- Pasithea also describes PAS‑004 as an allosteric inhibitor, meaning it binds a regulatory site on the enzyme (not the enzyme’s active site) to change activity.
- The solid tumor study lists an actual start date of February 29, 2024 and an estimated primary completion date of February 2026 on ClinicalTrials.gov.
- (fda.gov 1) (fda.gov 2) (federalregister.gov)
Quick answers
What happened in PAS‑004 fast‑tracked for NF1 plexiform neurofibromas?
The FDA granted fast track designation to PAS‑004, a macrocyclic MEK inhibitor being developed for NF1‑associated plexiform neurofibromas, accelerating its review path for a high‑morbidity rare disease. Fast track status typically means closer interactions with regulators and an expectation for rapid, rolling safety submissions as data accumulate. For rare‑disease programs this amplifies the need for near‑real‑time adverse event collection and clear REMS‑style planning if safety signals emerge. (targetedonc.com)
Why does PAS‑004 fast‑tracked for NF1 plexiform neurofibromas matter?
Pasithea Therapeutics (NASDAQ: KTTA) is the sponsor behind PAS‑004 and issued its announcement on April 1, 2026; the company lists two active early clinical programs for the molecule — an adult study for symptomatic plexiform neurofibromas linked to neurofibromatosis type 1 (ClinicalTrials.gov NCT06961565) and a separate Phase 1 dose‑escalation study in advanced solid tumors (ClinicalTrials.gov NCT06299839). (ir.pasithea.com) (clinicaltrials.gov 1) (clinicaltrials.gov 2) In company-disclosed interim human data, PAS‑004 has shown a tolerability profile dominated by low‑grade treatment‑related events to date and pharmacology consistent with prolonged systemic exposure that could support once‑daily oral dosing. (ascopubs.org) (ir.pasithea.com) PAS‑004 is described by the company as a macrocyclic MEK inhibitor; macrocyclic means the drug is built as a ring‑shaped molecule, which can improve stability and how long it stays in the body, and a MEK inhibitor blocks the enzymes MEK1 and MEK2 that relay growth signals through the mitogen‑activated protein kinase pathway (MAPK), a biochemical signaling chain that can drive tumor growth. Pasithea also describes PAS‑004 as an allosteric inhibitor, meaning it binds a regulatory site on the enzyme (not the enzyme’s active site) to change activity. (ir.pasithea.com) (ascopubs.org) The ongoing Phase 1 dose‑escalation study uses an open‑label modified “3+3” design — open‑label means investigators and patients know the drug being given, and “3+3” is a stepwise cohort scheme where small groups of patients receive escalating doses to find a tolerated range — and as of January 3, 2025 nine patients had been enrolled across 2 mg, 4 mg and 8 mg cohorts with no dose‑limiting toxicities reported; preliminary pharmacokinetic analysis estimated a terminal half‑life of about 70 hours and a steady‑state peak‑to‑trough ratio (Cmax/Cmin) of approximately 1.4. The solid tumor study lists an actual start date of February 29, 2024 and an estimated primary completion date of February 2026 on ClinicalTrials.gov. (ascopubs.org) (clinicaltrials.gov) Regulatory context: FDA expedited‑program guidance and internal procedures document how agencies handle products for serious, unmet‑need conditions and outline the authority to require post‑approval risk‑minimization measures; those same documents also describe sponsor‑agency interactions and program management that can lead to defined postmarketing commitments or risk management requirements later in the lifecycle. (fda.gov 1) (fda.gov 2) (fda.gov 3) Safety‑surveillance implications tied to the mechanism and early data are concrete: published experience with approved and investigational MEK inhibitors documents common class toxicities such as skin reactions and gastrointestinal effects, as well as less frequent but clinically important cardiac effects (reduced left ventricular ejection fraction, i.e., decreased heart pumping function) and ocular events including central serous retinopathy (fluid under the retina that can affect vision). FDA’s finalized best‑practices guidance for postmarketing safety surveillance and the agency’s REMS framework (Risk Evaluation and Mitigation Strategy, a formal safety program the agency can require) are the specific authorities and playbooks regulators cite when they seek protocolized monitoring, ocular/cardiac surveillance schedules, centralized adjudication, and post‑approval study commitments. (ascopubs.org) (accessdata.fda.gov) (academic.oup.com) (federalregister.gov) For teams drafting safety plans, the tangible takeaways in regulatory terms are already documented: expect agency reference to the REMS modification and implementation guidance timelines when proposing any risk‑minimization program, anticipate requests for structured post‑approval safety studies under existing accelerated‑approval statutes if efficacy endpoints are used for earlier approvals, and plan protocol language and data‑capture systems that support near‑real‑time adverse event aggregation and specialized adjudication (for example, ophthalmology and cardiology review paths) should the benefit‑risk calculus require formal mitigation. (fda.gov 1) (fda.gov 2) (federalregister.gov)
